Page 1 | Search Results | Blood Advances | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia

Richard M. Stone, Jessica K. Altman, Mikkael A. Sekeres

Blood Adv (2023) 7 (24): 7457–7458.

https://doi.org/10.1182/bloodadvances.2023009696

Published: 2023

Journal Articles

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies

Blood Adv (2023) 7 (20): 6120–6129.

https://doi.org/10.1182/bloodadvances.2023010061

Published: 2023

Includes: Supplemental data

Journal Articles

Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions

Blood Adv (2023) 7 (14): 3749–3759.

https://doi.org/10.1182/bloodadvances.2022008578

Published: 2023

Includes: Supplemental data

Journal Articles

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study

Blood Adv (2023) 7 (14): 3506–3515.

https://doi.org/10.1182/bloodadvances.2022009000

Published: 2023

Includes: Supplemental data

Journal Articles

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Maximilian Stahl, Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F. Sanz, David A. Sallman, Valeria Santini, Gail J. Roboz, Mrinal M. Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D. Nimer, Ravindra Majeti, Richard F. Little, Steven Gore, Alan F. List, Vijay Kutchroo, Rami S. Komrokji, Tae Kon Kim, Nina Kim, Christopher S. Hourigan, Robert P. Hasserjian, Stephanie Halene, Elizabeth A. Griffiths, Peter L. Greenberg, Maria Figueroa, Pierre Fenaux, Fabio Efficace, Amy E. DeZern, Matteo G. Della Porta, Naval G. Daver, Jane E. Churpek, Hetty E. Carraway, Andrew M. Brunner, Uma Borate, John M. Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P. Steensma, Mikkael A. Sekeres, Rena J. Buckstein, Amer M. Zeidan

Blood Adv (2023) 7 (12): 2709–2714.

https://doi.org/10.1182/bloodadvances.2022008747

Published: 2023

Journal Articles

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Blood Adv (2023) 7 (9): 1858–1870.

https://doi.org/10.1182/bloodadvances.2022008806

Published: 2023

Includes: Supplemental data

Journal Articles

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres

Blood Adv (2022) 6 (17): 5132–5145.

https://doi.org/10.1182/bloodadvances.2022007334

Published: 2022

Includes: Supplemental data

Journal Articles

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes

Blood Adv (2021) 5 (21): 4361–4369.

https://doi.org/10.1182/bloodadvances.2021004755

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

William A. Wood, Donna S. Neuberg, J. Colton Thompson, Martin S. Tallman, Mikkael A. Sekeres, Laurie H. Sehn, Kenneth C. Anderson, Aaron D. Goldberg, Nathan A. Pennell, Charlotte M. Niemeyer, Emily Tucker, Kathleen Hewitt, Robert M. Plovnick, Lisa K. Hicks

Blood Adv (2020) 4 (23): 5966–5975.

https://doi.org/10.1182/bloodadvances.2020003170

Published: 2020

Includes: Supplemental data

Journal Articles

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Blood Adv (2020) 4 (15): 3528–3549.

https://doi.org/10.1182/bloodadvances.2020001920

Published: 2020

Includes: Supplemental data

Journal Articles

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Blood Adv (2019) 3 (24): 4228–4237.

https://doi.org/10.1182/bloodadvances.2019000925

Published: 2019

Includes: Supplemental data

Journal Articles

Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years

Uma Borate, Brianna A. Norris, Abby Statler, Rongwei Fu, Taylor Bucy, Mikkael A. Sekeres

Blood Adv (2019) 3 (18): 2738–2747.

https://doi.org/10.1182/bloodadvances.2019000293

Published: 2019

Journal Articles

Distinct clinical and biological implications of CUX1 in myeloid neoplasms

Mai Aly, Zubaidah M. Ramdzan, Yasunobu Nagata, Suresh K. Balasubramanian, Naoko Hosono, Hideki Makishima, Valeria Visconte, Teodora Kuzmanovic, Vera Adema, Aziz Nazha, Bartlomiej P. Przychodzen, Cassandra M. Kerr, Mikkael A. Sekeres, Mohamed E. Abazeed, Alain Nepveu, Jaroslaw P. Maciejewski

Blood Adv (2019) 3 (14): 2164–2178.

https://doi.org/10.1182/bloodadvances.2018028423

Published: 2019

Includes: Supplemental data

Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Blood Adv (2019) 3 (6): 922–933.

https://doi.org/10.1182/bloodadvances.2018026989

Published: 2019

Includes: Supplemental data

Journal Articles

Subclonal STAT3 mutations solidify clonal dominance

Cassandra M. Kerr, Michael J. Clemente, Peter W. Chomczynski, Bartlomiej Przychodzen, Yasunobu Nagata, Vera Adema, Valeria Visconte, Alan E. Lichtin, Satu Mustjoki, Tomas Radivoyevitch, Mikkael A. Sekeres, Jaroslaw P. Maciejewski

Blood Adv (2019) 3 (6): 917–921.

https://doi.org/10.1182/bloodadvances.2018027862

Published: 2019

Includes: Supplemental data

Journal Articles

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia

Blood Adv (2019) 3 (3): 339–349.

https://doi.org/10.1182/bloodadvances.2018024216

Published: 2019

Includes: Supplemental data

Journal Articles

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet

Blood Adv (2018) 2 (16): 2063–2071.

https://doi.org/10.1182/bloodadvances.2018015529

Published: 2018

Includes: Supplemental data

Journal Articles

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Blood Adv (2018) 2 (14): 1765–1772.

https://doi.org/10.1182/bloodadvances.2018019414

Published: 2018

Journal Articles

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Blood Adv (2018) 2 (8): 923–932.

https://doi.org/10.1182/bloodadvances.2018016121

Published: 2018

Includes: Supplemental data

NARROW

Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies

Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years

Distinct clinical and biological implications of CUX1 in myeloid neoplasms

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Subclonal STAT3 mutations solidify clonal dominance

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only